• 
  Our Fieldwork Capability.

X Slider Background Settings

• Our Reach​.

  Now catering to the US, Canada, and the UK markets
• 

​Why Oncofocus?

---

In-house Panel

Verifothesis®, our in-house proprietary panel, allows quick access to even hard-to-reach healthcare professionals in the Asia-pacific region. We do not utilize external panels until and unless requested by client.

Experienced Team

Our team is our USP. We not only regularly conduct face-to-face interviews in India, Singapore, and Malaysia, but we also travel to US, EU, and other Asian countries to cover international conferences.

Technical Support

We understand that better quality of response in shorter TAT is only possible with active panel members. Verifothesis® and Glean® are our innovative tools for better panel engagement.

---

BCMA CAR-T Pipeline Landscape ​

​Focus: Multiple Myeloma Indication

click here

---

Our Services

---

Primary Market Research

We are a full-service Healthcare Market Research agency, operating primarily in the Oncology domain. Verifothesis®, our in-house proprietary panel tool, provides easy access to now >15,000 verified and active healthcare professionals from the APAC region. We strictly abide by ESOMAR market research guidelines. 

Some of our key PMR services are Physician perception mapping, Promotional strategy analysis, Positioning studies, and Pre- and Post-launch ATU studies.

Learn more

Competitive Intelligence

Oncofocus Competitive Intelligence team is adept in employing both primary and secondary research tools to create a comprehensive CI report. The standardized data collection process and framework-driven analytical approach enables us to provide a well-referenced strategic report that not only captures insights but also provokes questions on topics of strategic importance.
 
Some of our key CI services are Conference intelligence, Continuous monitoring, Clinical trial analysis, Pipeline landscape, and Publication analysis.

Learn more

Preclinical to Commercialization:
​Market Research support across all stages of drug development

Contact Us

Latest Research Work

---

Malignant melanoma is a complex, multifactorial disease causing ~75% of skin cancer deaths globally. Currently, 33 inhibitors are targeting PD-1/PD-L1 checkpoint molecules in 382 trials. Read more 

Multiple Myeloma is the second most common hematologic malignancy and is largely considered incurable. We found 47 BCMA targeting CAR-Ts under clinical development in Multiple Myeloma!!! Read more

---

A UK based diagnostics company providing Fluorescence in situ hybridization (FISH) based rapid tests has plans to enter the Indian market. We designed a Go-To-Market strategy and conducted a detailed market assessment. Click here to read our case study slide.

Read here the transcript of our interview with Dr Sujit Chakraborty, Clinical Oncologist from Hospital Lam Was Ee, Malaysia. He shared with us his experience on the basics of the Pancreatic cancer. ​​

---

Comments like these keep us going!!!